Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft

[News]

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.

More... (http://www.news-medical.net/news/20150530/Eisai-Phase-3-trial-of-eribulin-meets-primary-endpoint-in-patients-with-advanced-soft-tissue-sarcoma.aspx)